Since the onset of the Covid-19 pandemic, there have been multiple reports across the country of the very high incidence of mucormycosis among Covid-19 patients, especially in those who are diabetic and have received steroids.
Covid Associated Mucormycosis (CAM) has been associated with high morbidity and mortality, exorbitant treatment costs and has led to a shortage of antifungal drugs.
Fungal Infection Study Forum (FISF) releases recommendation on antifungal therapy in Covid associated mucormycosis when antifungal drug availability is limited:
• Antifungal prophylaxis is not recommended
• Start calculated dose of amphotericin B from first day, avoid dose
• Fluconazole, voriconazole, echinocandins (caspofungin,
anidulafungin, micafungin) or 5 flurocytosine is not active against
• Combination of antifungal therapy is generally not recommended
To know more, Checkout the below presentation:
Fungal Infection Study Forum